Your browser is no longer supported. Please, upgrade your browser.
Settings
VLRX Valeritas Holdings, Inc. daily Stock Chart
VLRX [NASD]
Valeritas Holdings, Inc.
Index- P/E- EPS (ttm)-6.17 Insider Own2.97% Shs Outstand25.06M Perf Week-59.56%
Market Cap10.18M Forward P/E- EPS next Y-1.90 Insider Trans- Shs Float19.02M Perf Month-67.49%
Income-50.30M PEG- EPS next Q-0.61 Inst Own27.40% Short Float17.48% Perf Quarter-68.98%
Sales23.40M P/S0.44 EPS this Y77.10% Inst Trans-2.82% Short Ratio4.09 Perf Half Y-73.26%
Book/sh0.15 P/B2.71 EPS next Y- ROA-108.80% Target Price3.50 Perf Year-85.28%
Cash/sh1.32 P/C0.31 EPS next 5Y- ROE- 52W Range0.39 - 6.79 Perf YTD-85.74%
Dividend- P/FCF- EPS past 5Y- ROI-141.90% 52W High-94.01% Beta-
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin45.30% 52W Low3.67% ATR0.13
Employees82 Current Ratio4.00 Sales Q/Q35.40% Oper. Margin- RSI (14)25.06 Volatility23.46% 13.75%
OptionableNo Debt/Eq13.68 EPS Q/Q66.00% Profit Margin- Rel Volume6.35 Prev Close0.40
ShortableYes LT Debt/Eq13.64 EarningsNov 09 BMO Payout- Avg Volume813.12K Price0.41
Recom2.00 SMA20-60.45% SMA50-64.44% SMA200-76.79% Volume4,721,704 Change2.89%
Jul-05-18Initiated Oppenheimer Outperform $3.50
Nov-18-18 07:31PM  Edited Transcript of VLRX earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 08:13PM  Valeritas Announces Pricing of $36 Million Public Offering GlobeNewswire -29.20%
Nov-14-18 07:35AM  Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry Discovering Underlying Factors of Influence GlobeNewswire -20.44%
Nov-13-18 07:00AM  Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar GlobeNewswire -14.39%
Nov-12-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese GlobeNewswire -6.94%
Nov-09-18 07:00AM  Valeritas Reports Record Revenue for the Third Quarter 2018 GlobeNewswire -10.00%
Nov-05-18 07:00AM  Valeritas to Report Third Quarter 2018 Results November 9, 2018 GlobeNewswire
Oct-19-18 07:00AM  Valeritas Announces That V-Go® Insulin Delivery Device Has Launched in Italy GlobeNewswire
Oct-17-18 07:00AM  Valeritas Wins Fifth Consecutive Cardinal Health Supply Chain Excellence Award GlobeNewswire
Oct-16-18 08:25AM  Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analyst Report ACCESSWIRE
Oct-15-18 07:00AM  Valeritas Expects to Report Record Revenue for Third Quarter 2018 GlobeNewswire -7.35%
Oct-11-18 07:00AM  Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit GlobeNewswire
Oct-10-18 07:00AM  Persistent Use of Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes GlobeNewswire
Oct-02-18 07:00AM  Valeritas V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes GlobeNewswire
Sep-26-18 08:00AM  Valeritas Begins Medical Device Registration Process in China for Its V-Go® Wearable Insulin Delivery Device GlobeNewswire +32.00%
Aug-23-18 07:00AM  Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia GlobeNewswire -9.17%
Aug-21-18 07:39PM  Edited Transcript of VLRX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -6.43%
Aug-07-18 04:05PM  Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth GlobeNewswire
02:30PM  Valeritas Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 07:00AM  Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia GlobeNewswire
Aug-02-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections GlobeNewswire
Aug-01-18 07:00AM  Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand GlobeNewswire
Jul-31-18 07:31AM  Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks ACCESSWIRE
Jul-25-18 07:00AM  Valeritas, Makers of V-Go® Insulin Delivery, is a Contributing Supporter of the Interactive Insulin Workshop at Two MEDS Conferences GlobeNewswire
Jul-24-18 07:00AM  Valeritas to Report Second Quarter 2018 Results August 7, 2018 GlobeNewswire
Jul-05-18 12:41PM  Valeritas Stock Should More Than Double, Oppenheimer Says Benzinga +8.88%
Jun-29-18 07:20AM  Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities ACCESSWIRE
Jun-26-18 08:05AM  Valeritas Holdings, New Study Results Pump Up V-Go Insulin Delivery Device ACCESSWIRE -6.83%
Jun-25-18 07:00AM  Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes GlobeNewswire +13.38%
May-23-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes GlobeNewswire
May-22-18 07:30AM  Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes ACCESSWIRE
07:10AM  Free Daily Technical Summary Reports on Valeritas and Three Other Medical Supplies Stocks ACCESSWIRE
May-21-18 07:00AM  Valeritas Announces V-Go® Distribution Agreement in Austria and Germany GlobeNewswire
May-18-18 07:00AM  Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes GlobeNewswire +10.42%
03:42AM  Edited Transcript of VLRX earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-16-18 07:50AM  Free Post Earnings Research Report: Integras Quarterly Sales Surged 38%; Adjusted EPS Soared 49% ACCESSWIRE
May-14-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes GlobeNewswire
May-09-18 04:01PM  Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6% GlobeNewswire
May-01-18 07:00AM  Valeritas to Report First Quarter 2018 Results on May 9, 2018 GlobeNewswire
Apr-30-18 07:00AM  Valeritas Presented New Data Demonstrating use of V-Go® Wearable Insulin Delivery Device Results in More Patients with Type 2 Diabetes Achieving Blood Glucose Targets GlobeNewswire
Apr-24-18 07:00AM  Valeritas Announces Pricing of $24 Million Public Offering of Common Stock GlobeNewswire -35.69%
Apr-20-18 07:00AM  Valeritas Teams with Glooko as its Preferred Data Management Partner for V-Go® SIM GlobeNewswire +76.27%
Apr-17-18 07:00AM  Valeritas Announces V-Go® Distribution Agreement in Australia and New Zealand GlobeNewswire +69.35%
Mar-02-18 07:00AM  Valeritas to Present at Upcoming Investor Conferences GlobeNewswire
Feb-28-18 06:48PM  Valeritas Holdings Inc (VLRX) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com +7.80%
Feb-27-18 04:21PM  Edited Transcript of VLRX earnings conference call or presentation 26-Feb-18 9:30pm GMT Thomson Reuters StreetEvents -5.37%
Feb-26-18 04:03PM  Valeritas Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
12:15PM  Valeritas Holdings, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-18 07:01AM  Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA GlobeNewswire
Feb-15-18 08:02AM  Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Ins... GlobeNewswire
Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery. In addition, its products include V-Go Prefill, which is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.